Friday, April 01, 2022
BioSig Technologies (BSGM)
Q4 2021 Misses But Pieces Are Falling In Place
BioSig Technologies, Inc. is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. PURE EP is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The PURE EP System has received FDA 510(k) clearance and installed its first commercial sale in February 2021. The company looks to apply their unique bioelectronic technology across additional disease conditions, including nervous system disorders, auto-immune diseases, hypertension, and pain.
Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q4 2021 reported. Yesterday, BioSig Technologies reported their fourth quarter, missing on top-line expectations, with no unit sales reported. That said, the company continues to roll out a phased commercialization strategy to promote faster revenue growth longer term.
Recent hires are expected to move the needle. In December 2021, the company introduced Gray Fleming as Chief Commercial Officer and acquired the services of Access Strategy Partners to assist in relationship management. Just last week, the company introduced John Sieckhaus as Chief Operating Officer. All these filled positions are upgrades or new positions that are expected to produce better …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
